patient subgroup...
age >= 60 yr age >= 65 yr corticosteroids: no corticosteroids: yes invasive ventilation non invasive oxygen subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
antiviral and associated therapy - versus potential COVID-19 treatments - for COVID 19 outpatients
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 0.28 [0.07, 1.04]< 1 37% 5 studies (5/-) 97.1 % some concern not evaluable moderate crucial - deaths 0.81 [0.56, 1.17]< 1 0% 15 studies (16/-) 87.2 % low low high crucial - deaths (time to event analysis only) 0.80 [0.43, 1.50]< 1 0% 1 study (1/-) 75.7 % NA not evaluable crucial - hospitalization or death 0.54 [0.34, 0.86]< 1 74% 9 studies (9/-) 99.5 % low not evaluable high crucial - A EFFACER PCR-negative (end of follow-up) 0.91 [0.57, 1.46]> 1 0% 1 study (1/-) 34.7 % NA not evaluable important - clinical deterioration 0.84 [0.68, 1.03]< 1 34% 7 studies (7/-) 95.0 % some concern not evaluable moderate important - clinical improvement 1.08 [1.00, 1.16]> 1 0% 4 studies (4/-) 98.1 % low not evaluable high important - clinical improvement (14-day) 1.12 [0.85, 1.47]> 1 13% 2 studies (2/-) 78.5 % some concern not evaluable moderate important - clinical improvement (21-day) 1.28 [0.79, 2.10]> 1 0% 1 study (1/-) 84.1 % NA not evaluable important - clinical improvement (28-day) 1.07 [0.97, 1.18]> 1 0% 1 study (2/-) 91.0 % NA not evaluable important - clinical improvement (time to event analysis only) 1.07 [1.00, 1.16]> 1 0% 3 studies (3/-) 97.0 % low not evaluable high important - hospitalization 0.74 [0.64, 0.86]< 1 0% 17 studies (17/-) 100.0 % some concern low moderate important - mechanical ventilation 1.08 [0.50, 2.31]< 1 0% 3 studies (3/-) 42.6 % some concern not evaluable moderate important - Recovery (time to event analysis only) 1.02 [0.92, 1.13]> 1 0% 1 study (1/-) 64.7 % NA not evaluable important - viral clearance 0.90 [0.76, 1.07]> 1 39% 6 studies (8/-) 11.9 % some concern not evaluable moderate important - viral clearance by day 14 0.79 [0.59, 1.07]> 1 48% 3 studies (4/-) 6.3 % some concern not evaluable moderate important - viral clearance by day 7 0.91 [0.69, 1.20]> 1 40% 6 studies (7/-) 25.5 % low not evaluable high important - emergency room observation for > 6 hours or hospitalization 0.64 [0.47, 0.87]< 1 0% 1 study (1/-) 99.8 % NA not evaluable non important - ICU admission 0.82 [0.45, 1.50]< 1 0% 2 studies (2/-) 73.5 % some concern not evaluable moderate non important - recovery 0.96 [0.86, 1.07]> 1 0% 1 study (1/-) 23.2 % NA not evaluable non important - 00 AE leading to drug discontinuation 0.79 [0.37, 1.69]< 1 60% 4 studies (4/-) 72.9 % some concern not evaluable moderate important - related AE (TRAE) 1.76 [1.10, 2.82]< 1 0% 1 study (1/-) 1.0 % NA not evaluable important - related SAE (TRSAE) 1.01 [0.25, 4.05]< 1 0% 1 study (1/-) 49.6 % NA not evaluable important - serious adverse events 0.53 [0.29, 0.98]< 1 27% 5 studies (5/-) 97.9 % low not evaluable high important - adverse events 2.31 [0.92, 5.82]< 1 96% 7 studies (7/-) 3.8 % some concern not evaluable moderate non important -
LoD: level of statistical demonstration:
